Evidence-based pharmacotherapy of Alzheimer's disease

The International Journal of Neuropsychopharmacology
John Grimley EvansJacqueline Birks

Abstract

Dementia is an acquired global impairment of cognitive capacities. Approximately 5% of people aged over 65 yr are affected by dementia, and some 70% of cases are thought to be due primarily to Alzheimer's disease. Descriptions of the clinical manifestations of Alzheimer's disease have been increasingly refined in the last decade but there is no diagnostic test for what remains fundamentally a pathologically defined condition. At the present time interventions for Alzheimer's disease are limited to those that modify the manifestations of the disease, and foremost amongst the candidates available are the cholinesterase inhibitors. The rationale for the use of cholinergic drugs for Alzheimer's disease lies in enhancing the secretion of, or prolonging the half-life of, acetylcholine in the brain. Several potential compounds have been tested, but short half-lives and a high incidence of cholinergic and other adverse effects have eliminated most. Only three are widely licensed for use, donepezil, galantamine and rivastigmine. Their efficacy is relatively modest. These drugs have been tested in 32 randomized, placebo-controlled trials. The trials assess cognitive function primarily, and in addition they may assess global function, act...Continue Reading

Citations

Nov 17, 2007·Aging Clinical and Experimental Research·Giovanni B FrisoniOrazio Zanetti
Jul 28, 2013·International Psychogeriatrics·Alexandra S CreightonDaniel W O'Connor
Mar 24, 2006·Journal of Child and Adolescent Psychopharmacology·Robert L FindlingEric A Youngstrom
Nov 22, 2011·Acta Crystallographica. Section B, Structural Science·Anaëlle TilborgJohan Wouters
Nov 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·R Overshott, A Burns
Aug 8, 2007·Neuropsychology Review·Ilse A D A van Halteren-van TilborgWouter Hulstijn
Sep 27, 2008·Expert Opinion on Drug Delivery·Hongbing WuXinguo Jiang
Dec 20, 2013·The International Journal of Neuroscience·Xiaojun WenJingyang Hu
May 23, 2012·Neuropsychologia·Paul S FosterValeria Drago
Apr 13, 2005·Geriatric Nursing·Marti D Buffum, John C Buffum
Sep 9, 2008·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Bethany SmithJonathon Symon
Nov 17, 2005·The Annals of Pharmacotherapy·David Q Pham, Roda Plakogiannis
Oct 3, 2008·Journal of Enzyme Inhibition and Medicinal Chemistry·Yanhong ShenYongzhou Hu
Feb 25, 2014·Journal of Young Pharmacists : JYP·Md Rezaul IslamSajib Chakraborty
Sep 7, 2018·Journal of Cellular Physiology·Mohammad Hosein FarzaeiSeyed Mohammad Nabavi
Aug 16, 2006·Phytotherapy Research : PTR·Vikas Kumar
Mar 23, 2006·Journal of the American Geriatrics Society·Jarmo AlanderTimo Klaukka
Jul 25, 2013·The Journal of Comparative Neurology·Melissa C DuffDaniel Tranel
Feb 24, 2006·The Journal of Pharmacology and Experimental Therapeutics·Teresa IuvoneAngelo A Izzo
Nov 1, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Vahid ShaygannejadNaser Zakizade
May 6, 2015·Drugs & Aging·Jacob S Buckley, Shelley R Salpeter
Oct 2, 2008·Journal of Gerontological Social Work·William D Cabin
May 12, 2009·Neuroscience and Behavioral Physiology·K V Voronkova, M N Meleshkov
Jun 23, 2006·Journal of Enzyme Inhibition and Medicinal Chemistry·José Correa-BasurtoJosé Trujillo-Ferrara
Jun 30, 2005·Journal of Pharmaceutical Sciences·Alexis Kays LeonardHenry R Costantino
Jul 6, 2005·Pharmacology & Therapeutics·Esa R Korpi, Saku T Sinkkonen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.